Rafferty Asset Management, LLC Ultragenyx Pharmaceutical Inc. Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 98,401 shares of RARE stock, worth $4.31 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

98,401

Previous 126,159 22.0%

Holding current value

$4.31 Million

Previous $5.19 Million 5.42%

% of portfolio

0.02%

Previous 0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$40.21 - $59.36 $1.12 Million - $1.65 Million	-27,758 Reduced 22.0%	98,401 $5.47 Million
Q2 2024 Aug 13, 2024	SELL	$37.42 - $51.61 $2.07 Million - $2.86 Million	-55,325 Reduced 30.48%	126,159 $5.19 Million
Q1 2024 May 13, 2024	SELL	$43.02 - $53.69 $1.74 Million - $2.17 Million	-40,426 Reduced 18.22%	181,484 $8.47 Million
Q4 2023 Feb 13, 2024	BUY	$31.73 - $49.19 $1.23 Million - $1.91 Million	38,859 Added 21.23%	221,910 $10.6 Million
Q3 2023 Nov 13, 2023	BUY	$34.92 - $46.66 $746,449 - $997,404	21,376 Added 13.22%	183,051 $6.53 Million
Q2 2023 Aug 11, 2023	SELL	$37.35 - $52.15 $519,165 - $724,885	-13,900 Reduced 7.92%	161,675 $7.46 Million
Q1 2023 May 11, 2023	SELL	$36.99 - $48.71 $840,597 - $1.11 Million	-22,725 Reduced 11.46%	175,575 $7.04 Million
Q4 2022 Feb 13, 2023	BUY	$33.72 - $46.33 $1.94 Million - $2.67 Million	57,610 Added 40.95%	198,300 $9.19 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $2.56 Million - $4.24 Million	64,107 Added 83.71%	140,690 $5.83 Million
Q2 2022 Aug 12, 2022	SELL	$45.8 - $85.4 $236,053 - $440,151	-5,154 Reduced 6.31%	76,583 $4.57 Million
Q1 2022 May 13, 2022	BUY	$62.2 - $84.4 $873,661 - $1.19 Million	14,046 Added 20.75%	81,737 $5.94 Million
Q4 2021 Feb 10, 2022	BUY	$73.71 - $87.86 $2.73 Million - $3.26 Million	37,052 Added 120.93%	67,691 $5.69 Million
Q3 2021 Nov 10, 2021	BUY	$77.92 - $102.4 $389,054 - $511,283	4,993 Added 19.47%	30,639 $2.76 Million
Q2 2021 Aug 10, 2021	SELL	$92.19 - $115.71 $55,221 - $69,310	-599 Reduced 2.28%	25,646 $2.45 Million
Q1 2021 May 10, 2021	BUY	$106.9 - $167.73 $2.12 Million - $3.32 Million	19,812 Added 307.97%	26,245 $2.99 Million
Q4 2020 Feb 10, 2021	SELL	$84.4 - $177.39 $1.73 Million - $3.63 Million	-20,440 Reduced 76.06%	6,433 $891,000
Q3 2020 Nov 13, 2020	BUY	$72.98 - $90.0 $937,063 - $1.16 Million	12,840 Added 91.5%	26,873 $2.21 Million
Q2 2020 Aug 07, 2020	BUY	$46.91 - $78.22 $344,084 - $573,743	7,335 Added 109.51%	14,033 $1.1 Million
Q1 2020 May 15, 2020	SELL	$33.8 - $62.9 $1.7 Million - $3.16 Million	-50,227 Reduced 88.23%	6,698 $298,000
Q4 2019 Feb 10, 2020	SELL	$36.08 - $45.83 $1.51 Million - $1.92 Million	-41,882 Reduced 42.39%	56,925 $2.43 Million
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $523,005 - $776,631	12,306 Added 14.23%	98,807 $4.23 Million
Q2 2019 Aug 09, 2019	BUY	$54.93 - $74.36 $1.18 Million - $1.6 Million	21,478 Added 33.03%	86,501 $5.49 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $2.59 Million - $4.51 Million	65,023 New	65,023 $4.51 Million

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.6M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.06B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Ultragenyx Pharmaceutical Inc. Transaction History